Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Grit Biotechnology
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1\. Voluntarily join the study, signed informed consent form,, willing and able to comply with the study protocol;
2\. Age 18 to 70 years old;
3\. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;
4\. Expected survival time of ≥ 12 weeks;
5\. Good function of vital organs;
6\. Subjects entering this study due to disease progression must have an imaging record of disease progression before tumor sampling;
7\. At least one measurable target lesion that meets the definition of RECIST v1.1 after tumor sampling.
You may not be if
1.Patients with uncontrollable tumor-related pain as judged by the investigator; participants requiring analgesic medication must already have a stable analgesic regimen at the time of study entry; symptomatic lesions suitable for palliative radiotherapy should be completed prior to study entry;
2.Known mental illness, alcoholism, drug use or substance abuse;
3.Pregnant or lactating women; or women who are pregnant, breastfeeding, or planning to become pregnant within 1 year after cell infusion;
4.Those who have received other clinical trial drug treatment within 4 weeks before preconditioning by lymphodepletion,plan to participate in other clinical trial drug treatment during the study;
5.The investigators determine that other conditions that make the patient not suitable for enrollment.
Clareo Health | GT201 Injection in Combination With Teraplizumab Injection for Treatment of Patients With Non-small Cell Lung Cancer
